Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to identifying and developing therapeutic solutions for pressing unmet needs in cancer care across the United States. The company's lead investigational compound, VIP152, functions as a cyclin-dependent kinase-9 (CDK9) inhibitor, specifically developed to treat patients afflicted with advanced cancer. Beyond its lead program, Vincerx Pharma's preclinical pipeline features VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor indications; and VIP943 and VIP924, both being explored for hematologic malignancies.